Lifecore Biomedical regains Nasdaq compliance, avoids delisting

LIFECORE BIOMEDICAL, INC. DE

Filed overdue Q3 FY2023 and Q1/Q2 FY2024 10-Qs on Aug 8, 2024, and FY2024 10-K on Aug 26, 2024.
Held 2024 annual meeting on Aug 15, 2024, curing Annual Meeting Rule deficiency.
Nasdaq will monitor compliance until Sept 4, 2025; further failure to file timely could lead to delisting without cure period.
Company's common stock remains listed on The Nasdaq Global Select Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.